Progyny Management
Management criteria checks 4/4
Progyny's CEO is Pete Anevski, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is $1.09M, comprised of 45.7% salary and 54.3% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $438.76K. The average tenure of the management team and the board of directors is 2.3 years and 7.1 years respectively.
Key information
Pete Anevski
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 45.7% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2.3yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03
Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital
May 06When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?
Jan 25Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue
Dec 12Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?
Oct 18Progyny Stock Should Deliver Superior Returns For Investors
Aug 05Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Jul 27At US$31.63, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 08Progyny: Solving Infertility Problem
Jul 05Progyny Stock: A Hidden Gem Tackling Infertility
May 31Investors Will Want Progyny's (NASDAQ:PGNY) Growth In ROCE To Persist
Apr 18At US$50.90, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
Mar 31Earnings Not Telling The Story For Progyny, Inc. (NASDAQ:PGNY)
Mar 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$500k | US$62m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$49m |
| Mar 31 2023 | n/a | n/a | US$43m |
| Dec 31 2022 | US$69m | US$500k | US$30m |
| Sep 30 2022 | n/a | n/a | US$42m |
| Jun 30 2022 | n/a | n/a | US$46m |
| Mar 31 2022 | n/a | n/a | US$56m |
| Dec 31 2021 | US$786k | US$425k | US$66m |
| Sep 30 2021 | n/a | n/a | US$90m |
| Jun 30 2021 | n/a | n/a | US$78m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$910k | US$425k | US$46m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$5m | US$375k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | US$1m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$682k | US$325k | -US$6m |
Compensation vs Market: Pete's total compensation ($USD1.09M) is below average for companies of similar size in the US market ($USD6.66M).
Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.
CEO
Pete Anevski (56 yo)
2.3yrs
Tenure
US$1,093,512
Compensation
Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.1yrs | US$513.57k | 0.0056% $ 174.4k | |
| CEO & Director | 2.3yrs | US$1.09m | 0.014% $ 438.8k | |
| President | 2.3yrs | US$1.49m | 0.066% $ 2.1m | |
| Chief Financial Officer | 3.6yrs | US$1.40m | 0% $ 0 | |
| Executive VP | 1.4yrs | US$546.22k | 0.012% $ 383.3k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Marketing Officer | no data | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Chief Business Development Officer | 2.3yrs | no data | no data | |
| Member of the Medical Advisory Board & Chief Medical Officer | less than a year | no data | no data | |
| Senior Vice President of Employer Market Strategy | 1.9yrs | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: PGNY's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.1yrs | US$513.57k | 0.0056% $ 174.4k | |
| CEO & Director | 2.3yrs | US$1.09m | 0.014% $ 438.8k | |
| Member of the Medical Advisory Board & Chief Medical Officer | no data | no data | no data | |
| Independent Director | 7.3yrs | US$567.30k | 0.42% $ 13.2m | |
| Independent Director | 9.1yrs | US$583.35k | 0.013% $ 393.0k | |
| Lead Independent Director | 13.9yrs | US$653.39k | 0.27% $ 8.4m | |
| Independent Director | 4.5yrs | US$518.30k | 0.0065% $ 200.9k | |
| Independent Director | 4.5yrs | US$606.88k | 0.013% $ 393.0k | |
| Member of the Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
7.1yrs
Average Tenure
64yo
Average Age
Experienced Board: PGNY's board of directors are considered experienced (7.1 years average tenure).